SCHEMBL23536615

SCHEMBL23536615

CC(OS(C)(=O)=O)c1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
HTT P42858 1/20 0.50
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.39
AGER Q15109 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
CNR1 P21554 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
KDM4E B2RXH2 1/20 0.36
KMT2A Q03164 1/20 0.36
CNR2 P34972 1/20 0.35
PKM P14618 1/20 0.35
LOX P28300 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15687372 0.82 ENPP2 (0.43) ALDH1A1LMNATSHR
SCHEMBL5326192 0.79 ALDH1A1 (0.37) ALDH1A1LMNAGAAMAPTKDM4E
SCHEMBL23536576 0.78 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2HTTGAA
SCHEMBL4734618 0.77 LMNA (0.55) ALDH1A1LMNASMN1; SMN2HTTGAA
SCHEMBL17789740 0.76 ALDH1A1 (0.41) ALDH1A1HTTGAAMAPTAGER
SCHEMBL3923775 0.74 ALDH1A1 (0.39) ALDH1A1LMNASMN1; SMN2HTTGAA
SCHEMBL6810966 0.74 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2HTTGAA
SCHEMBL8551002 0.74 ADRB2 (0.43) ALDH1A1CNR2TSHR
SCHEMBL18504414 0.74 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2
SCHEMBL2303018 0.74 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 US disclosed
EP-4192957-A2 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2023-06-14 EP disclosed
CN-116113698-A TRPML modulators 卡斯玛治疗公司 2023-05-12 CN disclosed
WO-2022032073-A2 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed
WO-2021127333-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 ALDH1A1 3737/4885LMNA 3324/4885SMN1; SMN2 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.